Published in Cancer Treat Rev on September 01, 1975
Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J (1980) 1.55
Progress report. Cancer of the pancreas. Gut (1977) 1.36
A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer (1989) 1.15
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer (2002) 1.09
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer (1996) 0.99
Human pancreatic adenocarcinoma line Capan-1 in tissue culture and the nude mouse: morphologic, biologic, and biochemical characteristics. Am J Pathol (1982) 0.97
Treatment of unresectable pancreatic cancer. Br Med J (Clin Res Ed) (1982) 0.90
Oncocytic-type intraductal papillary mucinous neoplasm (IPMN)-derived invasive oncocytic pancreatic carcinoma with brain metastasis - a case report. World J Surg Oncol (2012) 0.87
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas. Ann R Coll Surg Engl (1980) 0.84
Current approaches and future strategies for pancreatic carcinoma. Invest New Drugs (2000) 0.82
Progress report. Cytotoxic therapy for gastrointestinal carcinoma. Gut (1976) 0.79
Ifosfamide in advanced pancreatic cancer. A 5-year experience. Cancer Chemother Pharmacol (1986) 0.77
Update in cancer chemotherapy: gastrointestinal cancer, cancer of the pancreas. J Natl Med Assoc (1986) 0.77
Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells. Apoptosis (2014) 0.77
Is it relevant that intra-arterial chemotherapy may be effective for advanced pancreatic cancer? World J Gastroenterol (2007) 0.76
Capecitabine: an evidence-based review of its effectiveness in the treatment of carcinoma of the pancreas. Core Evid (2007) 0.75
Editorial: Pancreatic pain. Br Med J (1976) 0.75
Synthetic biliary bypass. Ann R Coll Surg Engl (1981) 0.75
PALA versus streptozotocin, doxorubicin, and MeCCNU in the treatment of patients with advanced pancreatic carcinoma. Invest New Drugs (1999) 0.75
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep (1976) 2.59
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol (1995) 1.67
The pulmonary toxicity of antineoplastic agents. Semin Oncol (1982) 1.65
Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results. J Natl Cancer Inst (1992) 1.61
A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol (1989) 1.56
Socioeconomic status and cancer survival. J Clin Oncol (1991) 1.48
Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. Cancer J Sci Am (2006) 1.38
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Cost effective Internet access and video conferencing for a community cancer network. Proc Annu Symp Comput Appl Med Care (1995) 1.28
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res (1991) 1.13
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol (1996) 1.07
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
The implementation of telemedicine within a community cancer network. J Am Med Inform Assoc (1997) 1.07
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res (1979) 1.05
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res (1989) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Noncorrelation of the expression of the c-myc oncogene in colorectal carcinoma with recurrence of disease or patient survival. Cancer Res (1988) 0.96
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest (1992) 0.95
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Small cell carcinoma of the lung. Cancer Treat Rev (1982) 0.93
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas. Invest New Drugs (1990) 0.92
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol (1990) 0.90
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Phase II trial of extended indications for resection is small cell carcinoma of the lung. J Thorac Cardiovasc Surg (1982) 0.88
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
Molecular alterations to human chromosome 3p loci in neuroendocrine lung tumors. Cancer (1998) 0.88
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
Perspectives on research in gynecologic oncology. Cancer (1976) 0.86
Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85
Pharmakokinetics and bioavailability study of ethacrynic acid as a modulator of drug resistance in patients with cancer. J Pharmacol Exp Ther (1994) 0.85
Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85
Phase I pharmacokinetic study of intraperitoneal etoposide. Cancer Res (1991) 0.84
Impaired interleukin regulation of the phytohemagglutinin response in Hodgkin's disease. Clin Immunol Immunopathol (1985) 0.84
Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys (1978) 0.83
Renal cell carcinoma: treatment with recombinant interleukin-2 plus beta-interferon. J Clin Oncol (1990) 0.83
The chemotherapy of head and neck cancer. Semin Oncol (1977) 0.83
Gastric cancer: current status of treatment. J Natl Cancer Inst (1977) 0.83
1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res (1972) 0.83
Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol (1984) 0.83
Abnormalities in water homeostasis in small cell anaplastic lung cancer. Cancer (1980) 0.83
Methyl-CCNU inclinical cancer therapy. Cancer Treat Rev (1974) 0.83
Bioavailability and pharmacokinetics of etoposide (VP-16). Semin Oncol (1985) 0.82
Selective surgical resection in small cell carcinoma of the lung. J Thorac Cardiovasc Surg (1979) 0.82
Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep (1978) 0.82
Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes. Cancer Res (1988) 0.82
A phase I and clinical pharmacology study of intravenously administered carminomycin in cancer patients in the United States. Cancer Res (1982) 0.82
A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81
Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. Adv Pharmacol Chemother (1975) 0.81
New drugs on the horizon in bronchogenic carcinoma. Cancer (1972) 0.81
Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an iv bolus. Cancer Treat Rep (1977) 0.81
The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat (1981) 0.81
Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81
Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol (1995) 0.81
Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treat Rev (1974) 0.80
Some thoughts on experimental models and their clinical correlations. Eur J Cancer (1975) 0.80
Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol (1984) 0.80
New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin (1975) 0.80
Current therapies in osteosarcoma. Cancer Treat Rev (1975) 0.80
Biologic effects of gamma interferon pre-treatment followed by monoclonal antibody 17-1A administration in patients with gastrointestinal carcinoma. Hybridoma (1986) 0.80
Oral etoposide in small-cell lung cancer. Semin Oncol (1986) 0.80
Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. J Natl Cancer Inst (1976) 0.80